However, we have examined the impact of nicorandil on the short-term prognosis only in patients with a first anterior AMI, and its influence on long-term prognosis remains unknown. The present study was designed to test the hypothesis that nicorandil improves the long-term clinical outcome in a large number of patients with anterior and non-anterior AMI. For this goal, we compared age-matched patients with a reperfused MI before and after intravenous infusion of nicorandil for routine treatment. We also used myocardial contrast echocardiography (MCE) to assess the impact of nicorandil treatment on tissue perfusion.
Methods

Study Population
This study was not a randomized trial and was based on retrospective analysis. We selected patients with AMI who were admitted to the Coronary Care Unit (CCU) from November 1997 to April 1998 and received intravenous infusion of nicorandil. We also selected patients with AMI in the similar time interval from November 1995 to April 1996. From those time intervals, 288 patients who were admitted to the CCU for AMI without hypotension and showed Thrombolysis in Myocardial Infarction (TIMI) 10 grade 0 or 1 at initial coronary angiography (CAG) were included in the study population. The diagnosis of AMI was made on the basis of chest pain of more than 30 min duration, ST segment elevation greater than 2 mm in 2 Circ J 2003; 67: 295 -300 (Received June 21, 2002 ; revised manuscript received December 19, 2002 ; accepted January 8, 2003) Division of Cardiology, Sakurabashi Watanabe Hospital and Departments of *Internal Medicine and Therapeutics and **Geriatric Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan Mailing address: Hiroshi Ito, MD, The Division of Cardiology, Sakurabashi Watanabe Hospital, 2-4-32 Umeda, Kita-ku, Osaka 530-0001, Japan. E-mail: itomd@osk4.3web.ne.jp contiguous electrocardiographic (ECG) leads and a more than 3-fold increase in serum creatine kinase (CK) activity. The exclusion criteria were age less than 18 years or more than 79 years, systolic blood pressure over 100 mmHg, cardiogenic shock, an underlying condition in which hypotension may be poorly tolerated for nicorandil infusion, and patients unlikely to be available for follow-up. Sixteen patients were excluded from analysis because of inadequate echo image quality. Therefore, this report is based on the remaining 272 patients. All patients underwent percutaneous transluminal coronary intervention (PCI) and achieved successful coronary reflow (TIMI grade 2 or 3) less than 24 h after the onset of symptoms. The subjects who gave the informed consent for this study protocol were recruited in the current investigation.
Study Protocol
In the nicorandil group, a bolus injection of 4 mg nicorandil (Sigmat, Chugai) was given just after the diagnosis of AMI was established. Nicorandil was continuously infused at 6 mg/h for 24 h followed by oral nicorandil at 15 mg/day until discharge (mean, 28 days) when the nicorandil treatment was ceased. In the control subjects, nicorandil treatment had never been given during follow up. All other protocols were the same in the 2 groups. Aspirin (243 mg) was given to each patient. After intravenous administration of heparin (100 U/kg), left and right CAG and left ventriculography (right anterior oblique view) were performed using the right femoral approach with Judkins' technique. Primary PCI was performed according to the protocol of the admitting hospital to achieve a residual diameter stenosis of less than 25%. A mean of 16 min after PCI, 2 ml sonicated Ioxaglate (Hexabrix-320, Tanabe) containing microbubbles with a mean size of 12 m was injected into the left or right coronary artery that was related to the infarct lesion to study the contrast reperfusion pattern. Echocardiograms were monitored using a mechanical sector scanner (SONOS100, Philips Medical Systems, carrier frequency of 3.5 MHz; MCE images were recorded on SVHS videotape (AG-6300, Panasonic). MCE images included the parasternal short-axis view at the mid-papillary muscle level and the apical 2-chamber and 4-chamber views.
The V5-equivalent lead ECG was continuously monitored for a mean of 5 days (range, 3-10 days) after the onset to detect arrhythmias. Two-dimensional echocardiography was performed on admission and on days 2, 3, 7, 14 and 21 as well as a mean of 3 months after the onset, with a commercially available electrical sector scanner (SONOS 2500 or 5500, Philips Medical Systems) and the images were recorded on 1.25 cm videotape of a magnetic optical disc. Coronary angiography and left ventriculography were repeated at a mean of 4 months after AMI.
Analysis of Echocardiographic Data
An experienced echocardiographer analyzed the MCE images independently to determine the presence or absence of the no-reflow phenomenon. [11] [12] [13] Myocardial reperfusion in the corresponding segment was considered incomplete (no-reflow) when the endocardial length of the contrast defect exceeded a quarter of that of the risk area. An independent investigator unaware of the clinical data analyzed wall motion in each study using a 16-segment model and the following scoring system: 4, dyskinetic; 3, akinetic; 2, severely hypokinetic; 1, hypokinetic; 0, normal. The wall motion score (WMS) was defined as the sum of the scores of the segments. We used WMS ( WMS = WMS 1 day -WMS 3 months) as the measure of improvement in wall motion.
Analysis of Ventriculographic Data
An angiographer unaware of the patients' data analyzed the left ventriculograms in the acute and late stages in a random sequence. End-diastolic volume and ejection fraction were measured with the area -length method. When left ventricular (LV) end-diastolic volume increased by more than 10% in the follow-up study, compared with the baseline study, we considered it indicative of LV remodeling.
Long-Term Follow-up
Follow-up data and the cardiac function of the patients were assessed in July 2000, by which time all patients had completed the follow-up period of 3 years (mean, 3.1±1.5 years; nicorandil group: 3.5±1.7 years, control group: 2.7± 1.2 years). Follow-up data included information on recurrent myocardial infarction (MI), congestive heart failure (CHF), repeated PCI, cardiac surgery, and death. Data were obtained from hospital charts and supplemented by the patients' general physicians, as well as by telephone interview with the patients or immediate relatives. The interview was conducted by a cardiologist unaware of the patients' clinical data. Deaths were classified as either cardiac or non-cardiac according to the diagnosis stated on the death certificate. Diagnoses were further confirmed by information from hospital charts, the patients' general physicians, or by immediate relatives of the patients. No patient was lost to follow-up.
Statistical Analysis
All continuous data are expressed as mean ± SD. Univariate analysis of differences between 2 groups was performed by one-way analysis of variance (ANOVA) (Scheffe F test) for continuous prognosis variables and by chi-squared test or Fisher exact test for discrete prognosis variables. Statistical analysis of temporal parameters was performed by Scheffe F test for repeated measures. Differences were considered significant at p<0.05.
Differences in long-term cardiac survival and cardiac event-free survival between subgroups were examined with the Kaplan-Meier method and associated log-rank test. The composite outcomes of the following cardiac events were employed in the analyses: cardiac death, recurrent MI, and CHF requiring hospitalization. Multivariate analysis of predictors of long-term cardiac event-free survival was performed using Cox's proportional hazard regression model. Forward-stepwise selection method was used to identify the variables remaining as independent risk factors for long-term survival (significant p value less than 0.05).
Variables included in the analysis were age, sex, onset-toreflow time, collateral grade, 14 use of nicorandil, use of a stent, use of an angiotensin-converting enzyme inhibitor (ACEI) and the no-reflow phenomenon. (Table 1) There were no differences between the 2 groups in age, sex, time from the onset of symptoms to reperfusion, frequency of prior infarction, collaterals (Retrop class ≥2), MI site, peak CK (IU/L) and coronary risk factors. Only the frequency of stent use was higher in the nicorandil group than in the control group. There was no difference in the use of diuretics, anti-arrhythmic agents and -blockers between the 2 groups except for the use of ACEI being more frequent in the nicorandil group.
Results
Patients' Background
To correct for the size and site of MI, we divided the patients in each group into those with an anterior AMI and those with a non-anterior wall AMI (Table 1) . There was no difference in the baseline characteristics between the nicorandil and control groups. Stent use and collaterals (Retrop class ≥2) were significantly more frequent in the nicorandil group than in the control group. (Table 2) The WMS was comparable between the 2 groups at baseline and it had decreased 3 months later in both groups. In the total population and in those with a non-anterior AMI, there was no difference in the late-stage WMS or the WMS between the 2 groups. In the anterior AMI group, however, the late-stage WMS was lower and WMS was higher in the nicorandil group than in the control group. The frequency of LV remodeling was significantly lower in the nicorandil group than in the control group in the total patients and in those with an anterior AMI. There was no difference in the frequency of LV remodeling between the 2 treatment groups in those with a non-anterior AMI. In the total patients, the frequency of the no-reflow phenomenon was lower in the nicorandil group, although this difference did not reach statistical significance (14% vs 23%, p=0.09) (Fig 1) . The frequency of the no-reflow phenomenon was lower in the nicorandil group than in the control group in the patients with an anterior AMI (17% vs 34%, p<0.03), but it was comparable between the 2 groups in those with a non-anterior MI (11% vs 11%, NS).
LV Functional Outcome and Microvascular Integrity
Late-Stage Prognosis
In the total patients, the frequencies of cardiac events and death from any cause were significantly lower in the 
Data are presented as mean value±SD. ∆WMS = WMS 1 day -WMS 3 months. LV dilation was defined as an increase in left ventricular end-diastolic volume >10% after 3 months.
Fig 1.
Comparison of frequency of no-reflow between the nicorandil and control groups using myocardial contrast echocardiography. In the total patients, the frequency of the no-reflow phenomenon was lower in the nicorandil group, although this difference did not reach statistical significance (14% vs 23%, p=0.09). The frequency of the no-reflow phenomenon was lower in the nicorandil group than in the control group in the patients with an anterior AMI (17% vs 34%, p<0.03), but it was comparable between the 2 groups in those with a non-anterior AMI (11% vs 11%).
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nicorandil group than in the control group (Table 3 ). In the anterior AMI group, the frequency of cardiac events and death from any cause was lower in the nicorandil group than in the control group. In the non-anterior AMI group, the frequency of reinfarction and cardiac events was lower in the nicorandial group than in the control group. The event-free curve of each group is shown in Fig 2 . The mean follow-up period was 3.1±1.5 years. The frequency of cumulative cardiac events, including CHF, reinfarction and cardiac death, was significantly lower in the nicorandil group than in the control group (p<0.02, Fig 2) . The major difference in the event-free curve was established in the acute stage and the difference gradually increased during the follow-up period.
We performed multiple logistic regression analysis to derive the factors related to cardiac events (Table 4) . Nicorandil treatment, male sex, age, stent use, collaterals, use of ACEI and -blockers, and peak CK concentration were selected by simple linear regression analysis to be factors related to cardiac events, and of these, nicorandil treatment was derived as a factor related to cardiac events (p=0.0011, odds ratio = 0.27, 95% confidence interval 0.12-0.58) by multiple regression analysis, and was able to reduce cardiac events by 63%.
Discussion
Clinical Impact of Nicorandil on Prognosis and Mechanism of AMI
The principal finding of this study is that nicorandil treatment in conjunction with PCI is associated with a better clinical and functional outcome until the late stage compared with reperfusion therapy alone. A major difference in the event-free curve was established within 1 month of AMI, and the difference gradually increased until the late stage. The higher event-free rate in the nicorandil group was attributed to the lower frequency of CHF and cardiac mortality. In patients with an anterior AMI, the better prognosis of the nicorandil group can be in part explained by better cardiac function and by the lower frequency of the LV remodeling that is associated with an increased frequency of CHF and sudden death. 15 Among factors related to patients' prognosis, success or failure of myocardial perfusion is an independent predictor of long-term cardiac death and cardiac events. Despite successful coronary recanalization, incomplete myocardial perfusion, the no-reflow phenomenon, is associated with a poor functional outcome, LV remodeling and a high mortality. 11, 16 In the total population, the frequency of the no-reflow phenomenon tended to be lower in the nicorandil group. In the patients with an anterior AMI, the frequency of the no-reflow phenomenon markedly decreased with nicorandil treatment, although it was comparable between the control and nicorandil groups in those with a non-anterior AMI. The result may in part explain the improved clinical and functional outcome associated with nicorandil treatment in patients with anterior AMI.
Several mechanisms of the beneficial impact of nicorandil treatment have been postulated. Satoh et al reported that nicorandil directly opens the KATP channels on the mitochondrial membrane at a much lower concentration than is required to open the same channels on the cell membrane. 9 The mitochondrial KATP channel is recognized as an end-effector of ischemic preconditioning. The dissipation of mitochondrial membrane potential reduces calcium influx. Opening the mitochondrial KATP channels could promote the binding of an endogenous mitochondrial ATPase inhibitor and thus conserve ATP during ischemia. A change in the mitochondrial membrane potential could alter glycolytic pathways during ischemia in favor of myocyte survival. Therefore, nicorandil should potentiate the tolerance of the heart and coronary microvasculature to ischemia 17 and could extend the period during which reperfusion therapy has a benefit. Nicorandil also reduces neutrophil infiltration into the ischemic myocardium 18, 19 and attenuates the activity of neutrophils, which would attenuate the microvascular injury caused by neutrophils, leading to maintenance of myocardial blood flow. In addition, vessels less than 100 m in diameter are sensitive to nicorandil and dilate to increase the blood flow, 20 which would augment the functional improvement of stunned myocardium, 21 and was reflected in the lower frequency of no-reflow in the nicorandil group than in the control group in patients with an anterior AMI. The benefit of nicorandil treatment also may be related to a hemodynamic effect that is characterized by a reduction of preload and/or afterload.
Impact of the Site of AMI on Prognosis
The clinical impact of nicorandil treatment differed according to the site of the infarction and we stratified the patients by MI location, anterior or non-anterior, at enrollment to ensure a balance in the size of the risk area, which is a well-known determinant of the final infarct size. Gibbons et al used radioimaging techniques to document that the anticipated benefit from improved reperfusion therapy is much greater and easier to detect in individual patients with an anterior AMI than in those with an inferior wall lesion, 22 which is mainly because of the greater size of the risk area in an anterior AMI. The results of the AMISTAD trial documented that the reduction in MI size by adenosine infusion in conjunction with thrombolysis is detected only in patients with an anterior lesion, 6 and our results concur with that observation. Among the present patients with an anterior AMI, improvement in LV function was significantly better and the frequency of LV dilation was significantly lower in the nicorandil group than in the control group. In contrast, there was no difference in latestage WMS and the frequency of LV dilation between the nicorandil and control groups among the patients with a non-anterior AMI. Only the frequency of cardiac events was lower in the nicorandil group in the follow-up study. The tendency for a larger infarct in patients with an anterior lesion was expected to result in a large absolute reduction in the infarct size with nicorandil, so the finding of a statistically significant difference in the treatment effect according to MI location was unexpected.
Although the reason for the minimal effect of nicorandil treatment in the non-anterior AMI group is unknown, there was no increase in adverse events. The first possible explanation relates to collateral circulation. Collateral flow is an independent predictor of infarct size, and the contribution of collateral flow to the preservation of myocardial and microvascular integrity may differ between patients with an anterior and non-anterior MI. In the present study, the frequency of collaterals (Retrop class ≥2) was significantly higher in the nicorandil group than in the control group among the patients with an anterior AMI. More of the nicorandil that was intravenously infused before PCI could reach the infarcted myocardium in the nicorandil group than in the control group is suggested as causing the reduction in the frequency of cardiac events especially in the nicorandil group. Moreover, among the patients with a non-anterior AMI, the frequency of cardiac events was significantly lower in the nicorandil group than in the control group, although there was no difference in the frequency of collaterals between the 2 groups, an effect also resulting from more of the intravenous nicorandil before PCI reaching the infarcted myocardium in the nicorandil group than in the control group. Second, the frequency of no-reflow phenomenon was much lower in a non-anterior AMI than in an anterior AMI among control patients (11% vs 34%, p<0.01). Because of better microvascular function at the moment of reperfusion, even in the control patients with a non-anterior AMI than in those with an anterior AMI, it is difficult to document a beneficial effect of nicorandil treatment. Finally, the lack of benefit in patients with a nonanterior AMI may simply be the result of chance. A greater number of study patients is required to establish the clinical value of nicorandil in patients with non-anterior AMI.
Study Limitations
The major drawback of this study was that it was not a randomized trial, which we could not conduct because we had previously established the benefit of nicorandil in a small cohort of patients with anterior AMI and have since then routinely used nicorandil. To eliminate the difference in other therapeutic modalities as much as possible, we selected patients who were admitted to the same CCU in a similar time interval before and after nicorandil treatment as a historical control. Baseline differences between the groups may have accounted for some of the observed differences. In fact, stents and ACEI use were more frequent in the nicorandil group than in the control group. Multiregression analysis, however, documented that neither of these were factors related to patient prognosis or functional outcome.
In most of the patients, nicorandil was given within 1 month of the onset of AMI. Experimental evidence suggests that nicorandil can augment cardioprotection through the pathway of ischemic preconditioning. But this was the case if nicorandil was given during the follow-up period. Further studies are required to determine whether or not the continuation of oral nicorandil would achieve an even better prognosis.
